Diseases of pulmonary surfactant homeostasis

Annual Review of Pathology: Mechanisms of Disease

Volumn 10, Issue , 2015, Pages 371-393

  Whitsett, Jeffrey A ^a,b   Wert, Susan E ^a,b   Weaver, Timothy E ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

alveolar capillary dysplasia; alveolar proteinosis; interstitial lung disease; pulmonary alveolar microlithiasis; pulmonary fibrosis; respiratory distress syndrome

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LUNG SURFACTANT; SODIUM PHOSPHATE COTRANSPORTER 2B; SURFACTANT ASSOCIATED PROTEIN;

ALVEOLAR CAPILLARY DYSPLASIA; ARTICLE; BREATHING; CELL DAMAGE; CHRONIC LUNG DISEASE; DYSPLASIA; FETUS LUNG MATURATION; GENE MUTATION; GENETIC DISORDER; GROUPS BY AGE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS; LUNG ALVEOLUS CELL; LUNG ALVEOLUS PROTEINOSIS; LUNG FIBROSIS; LUNG GAS EXCHANGE; MORPHOGENESIS; PATHOGENESIS; PREMATURITY; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; PULMONARY MICROLITHIASIS; RESPIRATORY DISTRESS SYNDROME; ANIMAL; GENETICS; LUNG; LUNG DISEASE; METABOLISM; NEONATAL RESPIRATORY DISTRESS SYNDROME;

ANIMALS; HOMEOSTASIS; HUMANS; LUNG; LUNG DISEASES; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 84921905250     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012513-104644     Document Type: Article

References (127)

1. Metzger RJ, Klein OD, Martin GR, Krasnow MA. 2008. The branching programme of mouse lung development. Nature 453:745-50
2. Perl AK, Wert SE, Nagy A, Lobe CG, Whitsett JA. 2002. Early restriction of peripheral and proximal cell lineages during formation of the lung. PNAS 99:10482-87
3. Morrisey EE, Hogan BL. 2010. Preparing for the first breath: genetic and cellular mechanisms in lung development. Dev. Cell 18:8-23
4. Warburton D, El-Hashash A, Carraro G, Tiozzo C, Sala F, et al. 2010. Lung organogenesis. Curr. Top. Dev. Biol. 90:73-158
5. Kimura S, Hara Y, Pineau T, Fernandez-Salguero P, Fox CH, et al. 1996. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 10:60-69
6. Que J, Luo X, Schwartz RJ, Hogan BL. 2009. Multiple roles for Sox2 in the developing and adult mouse trachea. Development 136:1899-907
7. Tompkins DH, Besnard V, Lange AW, Keiser AR, Wert SE, et al. 2011. Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am. J. Respir. Cell Mol. Biol. 45:101-10
8. Rockich BE, Hrycaj SM, Shih HP, Nagy MS, Ferguson MA, et al. 2013. Sox9 plays multiple roles in the lung epithelium during branching morphogenesis. PNAS 110:E4456-64
9. Hajihosseini MK, Wilson S, De Moerlooze L, Dickson C. 2001. A splicing switch and gain-of-function mutation in FgfR2-IIIc hemizygotes causes Apert/Pfeiffer-syndrome-like phenotypes. PNAS 98:3855-60
10. Zackai EH, McDonald-McGinn DM, Stolle C, Huff DS. 2003. Craniosynostosis with tracheal sleeve: a patient with Pfeiffer syndrome, tracheal sleeve and additional malformations in whom an FGFR2 mutation was found. Clin. Dysmorphol. 12:209
11. Kang S, Graham JM Jr, Olney AH, Biesecker LG. 1997. GLI3 frameshift mutations cause autosomal dominant Pallister-Hall syndrome. Nat. Genet. 15:266-68
12. Williamson KA, Hever AM, Rainger J, Rogers RC, Magee A, et al. 2006. Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum. Mol. Genet. 15:1413-22
13. Guillot L, Carre A, Szinnai G, Castanet M, Tron E, et al. 2010. NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in 'Brain-Lung-Thyroid Syndrome.' Hum. Mutat. 31:E1146-62
14. Hamvas A, Deterding RR, Wert SE, White FV, Dishop MK, et al. 2013. Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest 144:794-804
15. Stankiewicz P, Sen P, Bhatt SS, Storer M, Xia Z, et al. 2009. Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivatingmutations of FOXF1 cause alveolar capillary dysplasia and other malformations. Am. J. Hum. Genet. 84:780-91
16. Xu Y, Wang Y, Besnard V, Ikegami M, Wert SE, et al. 2012. Transcriptional programs controlling perinatal lung maturation. PLOS ONE 7:e37046
17. Avery ME, Mead J. 1959. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J. Dis. Child. 97:517-23
18. Whitsett JA, Wert SE, Weaver TE. 2010. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu. Rev. Med. 61:105-19
19. Bohinski RJ, Di Lauro R, Whitsett JA. 1994. The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis. Mol. Cell. Biol. 14:5671-81
20. DeFelice M, Silberschmidt D, DiLauro R, Xu Y, Wert SE, et al. 2003. TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. J. Biol. Chem. 278:35574-83
21. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, et al. 2013. European consensus guidelines on themanagement of neonatal respiratory distress syndrome in preterm infants-2013 update. Neonatology 103:353-68
22. Polin RA, Carlo WA, Comm. Fetus Newborn. 2014. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics 133:156-63
23. Bridges JP, Ludwig MG, Mueller M, Kinzel B, Sato A, et al. 2013. Orphan G protein-coupled receptor GPR116 regulates pulmonary surfactant pool size. Am. J. Respir. Cell Mol. Biol. 49:348-57
24. Yang MY, Hilton MB, Seaman S, Haines DC, Nagashima K, et al. 2013. Essential regulation of lung surfactant homeostasis by the orphan G protein-coupled receptor GPR116. Cell Rep. 3:1457-64
25. Clark JC, Wert SE, Bachurski CJ, Stahlman MT, Stripp BR, et al. 1995. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. PNAS 92:7794-98
26. Korfhagen TR, Bruno MD, Ross GF, Huelsman KM, Ikegami M, et al. 1996. Altered surfactant function and structure in SP-A gene targeted mice. PNAS 93:9594-99
27. Ikegami M, Whitsett JA, Jobe A, Ross G, Fisher J, Korfhagen T. 2000. Surfactant metabolism in SP-D gene-Targeted mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 279:L468-76
28. Ikegami M, Na CL, Korfhagen TR, Whitsett JA. 2005. Surfactant protein D influences surfactant ultrastructure and uptake by alveolar type II cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L552-61
29. McCormack FX, Whitsett JA. 2002. The pulmonary collectins, SP-A and SP-D, orchestrate innate immunity in the lung. J. Clin. Investig. 109:707-12
30. Kingma PS, Whitsett JA. 2006. In defense of the lung: surfactant protein A and surfactant protein D. Curr. Opin. Pharmacol. 6:277-83
31. Ariki S, Nishitani C, Kuroki Y. 2012. Diverse functions of pulmonary collectins in host defense of the lung. J. Biomed. Biotechnol. 2012:532071
32. Trapnell BC, Whitsett JA, Nakata K. 2003. Pulmonary alveolar proteinosis. N. Engl. J.Med. 349:2527-39
33. Perez-Gil J, Weaver TE. 2010. Pulmonary surfactant pathophysiology: current models and open questions. Physiology 25:132-41
34. Ikegami M, Grant S, Korfhagen T, Scheule RK, Whitsett JA. 2009. Surfactant protein-D regulates the postnatal maturation of pulmonary surfactant lipid pool sizes. J. Appl. Physiol. 106:1545-52
35. Wert SE, Whitsett JA, Nogee LM. 2009. Genetic disorders of surfactant dysfunction. Pediatr. Dev. Pathol. 12:253-74
36. Dishop MK. 2011. Paediatric interstitial lung disease: classification and definitions. Paediatr. Respir. Rev. 12:230-37
37. Kurland G, Deterding RR, Hagood JS, Young LR, Brody AS, et al. 2013. An official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy. Am. J. Respir. Crit. CareMed. 188:376-94
38. Vorbroker DK, Profitt SA, Nogee LM, Whitsett JA. 1995. Aberrant processing of surfactant protein C in hereditary SP-B deficiency. Am. J. Physiol. Lung Cell. Mol. Physiol. 268:L647-56
39. Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA. 2000. Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am. J. Respir. Crit. Care Med. 161:973-81
40. Whitsett JA, Weaver TE. 2002. Hydrophobic surfactant proteins in lung function and disease. N. Engl. J. Med. 347:2141-48
41. Nogee LM. 2004. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu. Rev. Physiol. 66:601-23
42. Dunbar AE 3rd, Wert SE, Ikegami M, Whitsett JA, Hamvas A, et al. 2000. Prolonged survival in hereditary surfactant protein B (SP-B) deficiency associated with a novel splicing mutation. Pediatr. Res. 48:275-82
43. Hamvas A. 2010. Evaluation and management of inherited disorders of surfactant metabolism. Chin. Med. J. 123:2943-47
44. Palomar LM, Nogee LM, Sweet SC, Huddleston CB, Cole FS, Hamvas A. 2006. Long-Term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J. Pediatr. 149:548-53
45. Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF. 2005. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am. J. Respir. Cell Mol. Biol. 32:521-30
46. Johansson H, Nordling K, Weaver TE, Johansson J. 2006. The Brichos domain-containing C-Terminal part of pro-surfactant protein C binds to an unfolded poly-val transmembrane segment. J. Biol. Chem. 281:21032-39
47. Glasser SW, Detmer EA, Ikegami M, Na CL, Stahlman MT, Whitsett JA. 2003. Pneumonitis and emphysema in sp-C gene targeted mice. J. Biol. Chem. 278:14291-98
48. Glasser SW, Witt TL, Senft AP, Baatz JE, Folger D, et al. 2009. Surfactant protein C-deficient mice are susceptible to respiratory syncytial virus infection. Am. J. Physiol. Lung Cell. Mol. Physiol. 297:L64-72
49. Glasser SW, Senft AP, Maxfield MD, Ruetschilling TL, Baatz JE, et al. 2013. Genetic replacement of surfactant protein-C reduces respiratory syncytial virus induced lung injury. Respir. Res. 14:19
50. Tanjore H, Blackwell TS, Lawson WE. 2012. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 302:L721-29
51. Kropski JA, Lawson WE, Young LR, Blackwell TS. 2013. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis. Model. Mech. 6:9-17
52. Thurm T, Kaltenborn E, Kern S, Griese M, Zarbock R. 2013. SFTPC mutations cause SP-C degradation and aggregate formation without increasing ER stress. Eur. J. Clin. Investig. 43:791-800
53. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. 2001. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med. 344:573-79
54. Nogee LM, Dunbar AE 3rd, Wert S, Askin F, Hamvas A, Whitsett JA. 2002. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest 121(Suppl.):20S-21S
55. Thomas AQ, Lane K, Phillips J 3rd, Prince M, Markin C, et al. 2002. Heterozygosity for a surfactant proteinCgene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am. J. Respir. Crit. Care Med. 165:1322-28
56. Katzenstein AL, Gordon LP, Oliphant M, Swender PT. 1995. Chronic pneumonitis of infancy. A unique form of interstitial lung disease occurring in early childhood. Am. J. Surg. Pathol. 19:439-47
57. Bridges JP, Xu Y, Na CL, Wong HR, Weaver TE. 2006. Adaptation and increased susceptibility to infection associated with constitutive expression of misfolded SP-C. J. Cell Biol. 172:395-407
58. Avital A, Hevroni A, Godfrey S, Cohen S, Maayan C, et al. 2014. Natural history of five children with surfactant protein C mutations and interstitial lung disease. Pediatr. Pulmonol. 49:1097-105
59. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, et al. 2004. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 59:977-80
60. van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, et al. 2010. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am. J. Respir. Crit. CareMed. 182:1419-25
61. Hepping N, Griese M, Lohse P, Garbe W, Lange L. 2013. Successful treatment of neonatal respiratory failure caused by a novel surfactant protein C p.Cys121Gly mutation with hydroxychloroquine. J. Perinatol. 33:492-94
62. Cheong N, Madesh M, Gonzales LW, Zhao M, Yu K, et al. 2006. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J. Biol. Chem. 281:9791-800
63. Matsumura Y, Ban N, Ueda K, Inagaki N. 2006. Characterization and classification of ATP-binding cassette transporter ABCA3 mutants in fatal surfactant deficiency. J. Biol. Chem. 281:34503-14
64. Matsumura Y, Ban N, Inagaki N. 2008. Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 295:L698-707
65. Weichert N, Kaltenborn E, Hector A, Woischnik M, Schams A, et al. 2011. Some ABCA3 mutations elevate ER stress and initiate apoptosis of lung epithelial cells. Respir. Res. 12:4
66. Brasch F, Schimanski S, Muhlfeld C, Barlage S, Langmann T, et al. 2006. Alteration of the pulmonary surfactant system in full-Term infants with hereditary ABCA3 deficiency. Am. J. Respir. Crit. CareMed. 174:571-80
67. Bullard JE, Wert SE, Nogee LM. 2006. ABCA3 deficiency: neonatal respiratory failure and interstitial lung disease. Semin. Perinatol. 30:327-34
68. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. 2004. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N. Engl. J. Med. 350:1296-303
69. Somaschini M, Nogee LM, Sassi I, Danhaive O, Presi S, et al. 2007. Unexplained neonatal respiratory distress due to congenital surfactant deficiency. J. Pediatr. 150:649-53.e1
70. Edwards V, Cutz E, Viero S, Moore AM, Nogee L. 2005. Ultrastructure of lamellar bodies in congenital surfactant deficiency. Ultrastruct. Pathol. 29:503-9
71. Doan ML, Guillerman RP, Dishop MK, Nogee LM, Langston C, et al. 2008. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 63:366-73
72. Young LR, Nogee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH. 2008. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest 134:192-95
73. Flamein F, Riffault L, Muselet-Charlier C, Pernelle J, Feldmann D, et al. 2012. Molecular and cellular characteristics of ABCA3 mutations associated with diffuse parenchymal lung diseases in children. Hum. Mol. Genet. 21:765-75
74. Cooke KR, Nishinakamura R, Martin TR, Kobzik L, Brewer J, et al. 1997. Persistence of pulmonary pathology and abnormal lung function in IL-3/GM-CSF/IL-5 βc receptor-deficient mice despite correction of alveolar proteinosis after BMT. Bone Marrow Transplant. 20:657-62
75. Reed JA, Ikegami M, Robb L, Begley CG, Ross G, Whitsett JA. 2000. Distinct changes in pulmonary surfactant homeostasis in common β-chain and GM-CSF-deficient mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 278:L1164-71
76. Trapnell BC, Whitsett JA. 2002. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu. Rev. Physiol. 64:775-802
77. Kitamura T, Tanaka N, Watanabe J, Uchida Kanegasaki S, et al. 1999. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 190:875-80
78. Martinez-Moczygemba M, Doan ML, Elidemir O, Fan LL, Cheung SW, et al. 2008. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRαgene in the X chromosome pseudoautosomal region 1. J. Exp. Med. 205:2711-16
79. Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, et al. 2008. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J. Exp. Med. 205:2703-10
80. Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, et al. 2010. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy.Am. J. Respir. Crit. CareMed. 182:1292-304
81. Dirksen U, Nishinakamura R, Groneck P, Hattenhorst U, Nogee L, et al. 1997. Human pulmonary alveolar proteinosis associated with a defect inGM-CSF/IL-3/IL-5 receptorcommonβchain expression. J. Clin. Investig. 100:2211-17
82. Tanaka T, Motoi N, Tsuchihashi Y, Tazawa R, Kaneko C, et al. 2011. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J. Med. Genet. 48:205-9
83. Suzuki T, Maranda B, Sakagami T, Catellier P, Couture CY, et al. 2011. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur. Respir. J. 37:201-4
84. Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC. 2010. Therapy options in pulmonary alveolar proteinosis. Ther. Adv. Respir. Dis. 4:239-48
85. Tazawa R, Trapnell BC, Inoue Y, Arai T, Takada T, et al. 2010. Inhaled granulocyte/macrophagecolony stimulating factor as therapy for pulmonary alveolar proteinosis. Am. J. Respir. Crit. CareMed. 181:1345-54
86. Luisetti M, Kroneberg P, Suzuki T, Kadija Z, Muellinger B, et al. 2011. Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer. Pulm. Pharmacol. Ther. 24:123-27
87. Malur A, Kavuru MS, Marshall I, Barna BP, Huizar I, et al. 2012. Rituximab therapy in pulmonary alveolar proteinosis improves alveolar macrophage lipid homeostasis. Respir. Res. 13:46
88. Leth S, Bendstrup E, Vestergaard H, Hilberg O. 2013. Autoimmune pulmonary alveolar proteinosis: treatment options in year 2013. Respirology 18:82-91
89. Lachmann N, Happle C, Ackermann M, Luttge D, Wetzke M, et al. 2014. Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. Am. J. Respir. Crit. Care Med. 189:167-82
90. Suzuki T, Mayhew C, Sallese A, Chalk C, Carey BC, et al. 2014. Use of induced pluripotent stem cells to recapitulate pulmonary alveolar proteinosis pathogenesis. Am. J. Respir. Crit. CareMed. 189:183-93
91. Price M, Lazzaro D, Pohl T, Mattei MG, Ruther U, et al. 1992. Regional expression of the homeobox gene Nkx-2.2 in the developing mammalian forebrain. Neuron 8:241-55
92. Galambos C, Levy H, Cannon CL, Vargas SO, Reid LM, et al. 2010. Pulmonary pathology in thyroid transcription factor-1 deficiency syndrome. Am. J. Respir. Crit. Care Med. 182:549-54
93. Kleinlein B, Griese M, Liebisch G, Krude H, Lohse P, et al. 2011. Fatal neonatal respiratory failure in an infant with congenital hypothyroidism due to haploinsufficiency of the NKX2-1 gene: alteration of pulmonary surfactant homeostasis. Arch. Dis. Child. Fetal Neonatal Ed. 96:F453-56
94. Iwatani N, Mabe H, Devriendt K, Kodama M, Miike T. 2000. Deletion of NKX2.1 gene encoding thyroid transcription factor-1 in two siblings with hypothyroidism and respiratory failure. J. Pediatr. 137:272-76
95. Maquet E, Costagliola S, Parma J, Christophe-Hobertus C, Oligny LL, et al. 2009. Lethal respiratory failure and mild primary hypothyroidism in a term girl with a de novo heterozygous mutation in the TITF1/NKX2.1 gene. J. Clin. Endocrinol. Metab. 94:197-203
96. Salerno T, Peca D, Menchini L, Schiavino A, Petreschi F, et al. 2014. Respiratory insufficiency in a newborn with congenital hypothyroidism due to a new mutation of TTF-1/NKX2.1 gene. Pediatr. Pulmonol. 49:E42-44
97. Barnett CP, Mencel JJ, Gecz J, Waters W, Kirwin SM, et al. 2012. Choreoathetosis, congenital hypothyroidism and neonatal respiratory distress syndrome with intact NKX2-1. Am. J. Med. Genet. A 158A:3168-73
98. Kalinichenko VV, Lim L, Stolz DB, Shin B, Rausa FM, et al. 2001. Defects in pulmonary vasculature and perinatal lung hemorrhage in mice heterozygous null for the Forkhead Box f1 transcription factor. Dev. Biol. 235:489-506
99. Rabah R, Poulik JM. 2001. Congenital alveolar capillary dysplasia with misalignment of pulmonary veins associated with hypoplastic left heart syndrome. Pediatr. Dev. Pathol. 4:167-74
100. Alameh J, Bachiri A, Devisme L, Truffert P, Rakza T, et al. 2002. Alveolar capillary dysplasia: a cause of persistent pulmonary hypertension of the newborn. Eur. J. Pediatr. 161:262-66
101. Antao B, Samuel M, Kiely E, Spitz L, Malone M. 2006. Congenital alveolar capillary dysplasia and associated gastrointestinal anomalies. Fetal Pediatr. Pathol. 25:137-45
102. Miranda J, Rocha G, Soares P, Morgado H, Baptista MJ, et al. 2013. A novel mutation in FOXF1 gene associated with alveolar capillary dysplasia with misalignment of pulmonary veins, intestinal malrotation and annular pancreas. Neonatology 103:241-45
103. Nguyen L, Riley MM, Sen P, Galambos C. 2013. Alveolar capillary dysplasia with misalignment of pulmonary veins with a wide spectrum of extrapulmonary manifestations. Pathol. Int. 63:519-21
104. Sen P, Yang Y, Navarro C, Silva I, Szafranski P, et al. 2013. Novel FOXF1 mutations in sporadic and familial cases of alveolar capillary dysplasia with misaligned pulmonary veins imply a role for its DNA binding domain. Hum. Mutat. 34:801-11
105. Kolble K, Lu J, Mole SE, Kaluz S, Reid KB. 1993. Assignment of the human pulmonary surfactant protein D gene (SFTP4) to 10q22-q23 close to the surfactant protein A gene cluster. Genomics 17:294-98
106. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, et al. 2009. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 84:52-59
107. Maitra M, Wang Y, Gerard RD, Mendelson CR, Garcia CK. 2010. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J. Biol. Chem. 285:22103-13
108. Maitra M, Cano CA, Garcia CK. 2012. Mutant surfactant A2 proteins associated with familial pulmonary fibrosis and lung cancer induce TGF-β1 secretion. PNAS 109:21064-69
109. Maitra M, Dey M, Yuan WC, Nathanielsz PW, Garcia CK. 2013. Lung fibrosis-Associated surfactant protein A1 and C variants induce latent transforming growth factor β1 secretion in lung epithelial cells. J. Biol. Chem. 288:27159-71
110. Ferreira Francisco FA, Pereira e Silva JL, Hochhegger B, Zanetti G, Marchiori E. 2013. Pulmonary alveolar microlithiasis. State-of-The-Art review. Respir. Med. 107:1-9
111. Corut A, Senyigit A, Ugur SA, Altin S, Ozcelik U, et al. 2006. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am. J. Hum. Genet. 79:650-56
112. Huqun Izumi S, Miyazawa H, Ishii K, Uchiyama B, et al. 2007. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am. J. Respir. Crit. CareMed. 175:263-68
113. Yin X, Wang H, Wu D, Zhao G, Shao J, Dai Y. 2013. SLC34A2 gene mutation of pulmonary alveolar microlithiasis: report of four cases and review of literatures. Respir. Med. 107:217-22
114. Ozcelik U, Yalcin E, Ariyurek M, Ersoz DD, Cinel G, et al. 2010. Long-Term results of disodium etidronate treatment in pulmonary alveolar microlithiasis. Pediatr. Pulmonol. 45:514-17
115. Garcia CK, Wright WE, Shay JW. 2007. Human diseases of telomerase dysfunction: insights into tissue aging. Nucleic Acids Res. 35:7406-16
116. Armanios M. 2012. Telomerase and idiopathic pulmonary fibrosis. Mutat. Res. 730:52-58
117. Gansner JM, Rosas IO. 2013. Telomeres in lung disease. Transl. Res. 162:343-52
118. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356:1317-26
119. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, et al. 2007. Adult-onset pulmonary fibrosis caused by mutations in telomerase. PNAS 104:7552-57
120. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, et al. 2008. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. PNAS 105:13051-56
121. Alder JK, Cogan JD, Brown AF, Anderson CJ, Lawson WE, et al. 2011. Ancestralmutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLOS Genet. 7:e1001352
122. Mushiroda T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, et al. 2008. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J. Med. Genet. 45:654-56
123. Parry EM, Alder JK, Qi X, Chen JJ, Armanios M. 2011. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood 117:5607-11
124. Fernandez BA, Fox G, Bhatia R, Sala E, Noble B, et al. 2012. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir. Res. 13:64
125. Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, et al. 2010. Telomere lengths, pulmonary fibrosis and telomerase (TERT ) mutations. PLOS ONE 5:e10680
126. Garcia CK. 2011. Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc. Am. Thorac. Soc. 8:158-62
127. Devine MS, Garcia CK. 2012. Genetic interstitial lung disease. Clin. Chest Med. 33:95-110